Podcasts about clarivate

Today we speak to David Erritzoe (Clin Associate Professor in Psychopharmacology & Psychiatry) .A leading researcher in the science of psychedelics, addiction, and mental health, David joins us to unpack what's actually happening in the brain when patterns break, beliefs loosen, and change becomes possible. Together, we explore the tension between biology and meaning, evidence and experience — and what modern neuroscience can (and can't) tell us about transformation.This conversation sits right at the heart of the journey: a moment to question assumptions, re-examine what we think we know about the mind, and consider how altered states — whether clinical, chemical, or contemplative — might reshape the stories we tell about ourselves.David is a highly cited scientist (top 0.1% globally in 2025, Clarivate), and in 2025 received Imperial's President Award for Excellence in Research, and his team has received several additional awards in recent years. David and his team have been awarded competitive grant & fellowship funding, hereunder from MRC/UKRI, NIHR and Welcome Trust. David has published 150+ scientic papers, contributed to 7 books (incl author of 6 book chapters), an per Dec 2025 has a Scopus h-index of 54 and 19k+ citations. Hosted on Acast. See acast.com/privacy for more information.

Which bio/pharmaceuticals, slated to be launched or approved in 2026, may be potential blockbusters or are raising the innovation bar to new heights? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, highlights the 11 drugs making Clarivate's Drugs to Watch list in 2026, key trends in product innovation, and the companies and products on the industry's radar. Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking advancements and strategic movements shaping the future of healthcare.The pharmaceutical and biotech sectors are undergoing significant transformations, driven by scientific breakthroughs, regulatory developments, and strategic shifts. At the forefront is Eli Lilly's impressive lineup of investigational cardiometabolic drugs, spotlighted in Clarivate's "Drugs to Watch in 2026" report. This signals a robust focus on combating cardiometabolic disorders, which have vast implications for global health due to their widespread prevalence. The report also highlights Johnson & Johnson's competitive position in this therapeutic area, indicating a dynamic landscape where innovation is key.In oncology, Jazz Pharmaceuticals is making waves with its bispecific antibody, Ziihera, positioning it as a preferred HER2-targeted therapy for stomach cancer. This development marks a shift towards precision medicine and targeted therapies, which are gradually supplanting traditional treatments like Herceptin. The promising efficacy of Ziihera could revolutionize treatment protocols for HER2-positive gastric cancer patients, enhancing survival outcomes and quality of life.Meanwhile, a legal confrontation has erupted between Bayer and leading COVID-19 vaccine developers such as Moderna, Johnson & Johnson, and Pfizer-BioNTech. Bayer alleges patent infringement on intellectual property developed years prior. This lawsuit underscores the intricate relationship between innovation and intellectual property rights in the pharmaceutical industry, especially poignant in the aftermath of the COVID-19 pandemic.Daiichi Sankyo's collaboration with Genesis to commercialize Vanflyta—an acute myeloid leukemia treatment—across 13 European countries highlights strategic movements in oncology. Approved in 2023, this partnership exemplifies Daiichi's commitment to expanding its European market presence and improving patient access to critical cancer therapies.GSK's promising Phase 3 results for its hepatitis B drug candidate represent a potential breakthrough as a "functional cure." Such advancements could redefine management strategies for hepatitis B, a chronic infection affecting millions worldwide. The positive trial outcomes pave the way for FDA submission, showcasing GSK's dedication to addressing unmet medical needs through innovative approaches.Amgen's strategic partnership with Disco Pharmaceuticals illustrates ongoing investment in oncology research. With a $618 million agreement focused on cancer target discovery, Amgen leverages Disco's expertise to fortify its oncology pipeline. This collaboration underscores the significance of cooperative innovation in drug development and enhancing therapeutic options.In gene therapy, Ikarovec and VectorBuilder are advancing eye disease treatments through an innovative partnership. Their $1 billion deal aims to make gene therapies more accessible by enabling administration outside specialized settings—a transformative approach that could democratize advanced treatments.Hope Biosciences' Phase 2 study results offer hope for Parkinson's disease patients through stem cell therapy improvements in motor function. Despite some data discrepancies, these findings set the stage for Phase 3 trials and underscore the potential of stem cell therapies in neurological disorders.The pharmaceutical industry also grapples with economic challenges as layoffs rise by 16% year-over-year in 2025. Concurrently, despite regulatory hurdles and macroeconomic uncertainties, the FDA approved 55 new treatments and vaccines—a testament to resilience and innovation within biopharma.In regulatory dynamics, GSK's Exdensur received approval in Japan for treating severe asthma and chronic rhinosinusitisSupport the show

Comenzamos esta reacción en cadena conociendo a Rocío Álvarez, alma de estos premios que dedicó a su padre José Álvarez Álvarez, y que ha acogido el Ayuntamiento de Caravaca, con el objetivo de fomentar la investigación y la igualdad en la ciencia. En esta primera edición las premiadas son Ana Martínez Vacas a la que conocemos con su proyecto de investigación en enfermedades oftalmológicas que compagina con sus estudios en Medicina.También conocemos a Pablo Pelegrín, investigador de la UMU, es uno de los científicos más influyentes del mundo según el rankin Clarivate 2025.

Which bio/pharmaceuticals, launched or approved thus far in 2025, may be potential blockbusters (defined as drugs with sales of $1 billion or more) in the mid term, and what upcoming launches or approvals and trends should be on the industry's radar? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, provides the latest developments and insights.  Support the show

Today's guest is Christo Siebrits, Senior Associate and General Counsel at AbbVie. With over 20 years of experience in global pharmaceutical legal and compliance leadership, Siebrits leads AbbVie's AI initiatives and provides strategic guidance on AI-related legal and regulatory matters. Christo joins Emerj Editorial Director Matthew DeMello to discuss how enterprise legal teams can adopt generative AI safely, balance internal versus external data use, and implement human-in-the-loop workflows to manage risk. Siebrits also shares practical strategies for matter-centric processes, measuring AI-driven efficiencies, and making informed decisions on AI investments across internal and external legal operations. We'd like to note for our audience that the views expressed by Christo on today's program do not reflect those of AbbVie or its leadership. Have a story about AI adoption you're ready to share with fellow enterprise leaders? Visit emerj.com/expert2 to explore the opportunity to be a featured guest on the ‘AI in Business podcast'. This episode is sponsored by Clarivate. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.

Today's guest is Shandon Quinn, Vice President of Patent Intelligence, Search and Analytics at Clarivate. Quinn joins Emerj Editorial Director Matthew DeMello to examine how AI-powered workflows are helping IP leaders deliver strategic impact, smarter decision-making, and tangible results for data-centric enterprises. Shandon also shares proven changes to patent review and portfolio management, including the shift to predictive analytics and benchmarking, enabling teams to save costs and create new business value through data and automation. This episode is sponsored by Clarivate. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast!

This episode features Dr. Paul Cotter PhD of TEAGASC in Ireland, talking about the creation of fermented foods and how they can lead to health benefits. A huge array of foods can be fermented, and historically fermentation was used to extend the shelf life of a food that people had an abundance of. Dr. Cotter's work in the field originally started with a bacteria-killing bacteriocin that had been isolated from kefir, and later moved toward the microbes in fermented foods. Currently he's interested in comparing the artisanal approach to fermented foods, which leads to somewhat unpredictable results in the final products, with the industrial approach, which leads to more consistent results. In different artisanal fermented foods, which strains are common and which are unique? Potentially some of the strains can be used to confer a health benefit, and even a benefit that's personalized to an individual. Dr. Cotter sees the role of fermented foods as possibly targeting pre-disease rather than disease if their ability to confer health benefits can be unravelled further. Episode abbreviations and links: Paper in Cell showing huge microbial diversity in foods: Unexplored microbial diversity from 2,500 food metagenomes and links with the human microbiome DOMINO research project website Additional resources: ISAPP infographic: Fermented foods About Dr. Paul Cotter PhD: Prof Paul Cotter is the Head of Food Biosciences at Teagasc (the Irish Agriculture and Food Development Authority), is a Principal Investigator with the large Irish Research Centres, APC Microbiome Ireland, VistaMilk and Food for Health Ireland and head of microbiology/co-founder of SeqBiome, a microbiome sequencing and bioinformatics service provider. He is a molecular microbiologist, with a particular focus on the microbiology of foods (especially fermented foods), the food systems and of humans, as well as probiotics and postbiotics. Prof Cotter is the author of >400 peer-reviewed, was included in the Clarivate list of highly cited researchers for 2018-2024, received an honorary doctorate from the University of Antwerp in 2024 and is the Field Chief Editor of Frontiers in Microbiology.

The Stanford Business School professor Michal Kosinski has spent his career warning about the corrosive impact of technology, and particularly social media, on democratic institutions and individual freedom. The Polish born academic gained notoriety for his research at Cambridge University on how social media data could predict intimate personal traits. His work became particularly relevant during the Cambridge Analytica scandal in 2016, leading to significant legal consequences for Facebook, including a $50 billion fine. In this KEEN ON conversation with Kosinski, recorded in Munich at DLD, he emphasizes that Facebook wasn't inherently malicious but failed to understand the full implications of their intrusive technology. Kosinksi connects social media's rise with the growth of populism, explaining how platforms enabled figures like Trump and even Bernie Sanders to bypass traditional political gatekeepers. Kosinski also discusses his controversial 2017 research showing that AI can predict personal characteristics, including sexual orientation, from facial features. On privacy, Kosinski believes that complete privacy protection may be impossible in the modern digital age. Instead, he advocates for building social and legal systems that make privacy invasions less dangerous. Looking to the future, Kosinski expresses short-term optimism about AI's potential to improve lives but long-term concern about the risks of artificial general intelligence (AGI). He notes that while we may see increased prosperity and advancement in the near future, the exponential acceleration of technological progress means long-term risks could materialize much sooner than expected.Michal Kosinski is an Associate Professor of Organizational Behavior at Stanford Graduate School of Business. His research interests encompass both human and artificial cognition. His current work centers on examining the psychological processes in Large Language Models and leveraging Artificial Intelligence, Machine Learning, Big Data, and computational techniques to model and predict human behavior. He co-authored Handbook of Social Psychology and Modern Psychometrics, two popular textbooks, and has published over 100 peer-reviewed papers in prominent journals such as Proceedings of the National Academy of Sciences, Nature Computational Science, Psychological Science, Journal of Personality and Social Psychology, Machine Learning, and Scientific Reports, which have been cited over 22,000 times. He is among the Top 1% of the Highly Cited Researchers according to Clarivate. His research has inspired a cover of The Economist, a 2014 theatre production titled “Privacy,” several TED talks, and a video game. It has been featured in thousands of press articles, books, podcasts, and documentaries. He received a Rising Star award from the Association of Psychological Science (2015) and an Early Achievement Award from the European Association of Personality Psychology (2023). He was behind the first press article warning against Cambridge Analytica. His research exposed the privacy risks they exploited and assessed the effectiveness of their methods. More about his role in uncovering their actions can be found in Steven Levy's insightful book Facebook: The Inside Story and Sander van der Linden's article, “Weapons of Mass Persuasion.” He earned a PhD in psychology from the University of Cambridge and two master's degrees in psychometrics and social psychology. Before his current appointment, he held positions as a post-doctoral scholar in Stanford's Computer Science Department, Deputy Director of the University of Cambridge Psychometrics Centre, and a researcher in Microsoft Research's Machine Learning Group.Named as one of the "100 most connected men" by GQ magazine, Andrew Keen is amongst the world's best known broadcasters and commentators. In addition to presenting KEEN ON, he is the host of the long-running How To Fix Democracy show. He is also the author of four prescient books about digital technology: CULT OF THE AMATEUR, DIGITAL VERTIGO, THE INTERNET IS NOT THE ANSWER and HOW TO FIX THE FUTURE. Andrew lives in San Francisco, is married to Cassandra Knight, Google's VP of Litigation & Discovery, and has two grown children.Keen On is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit keenon.substack.com/subscribe

In this episode, we meet Dr. Sam Gosling, author of "Snoop:  What Your Stuff Says About You" who shares his scientific insights into how personality and character can determine how we express ourselves in our intimate spaces.    Sam Gosling is a Professor of Psychology at the University of Texas, Austin. His research focuses on the psychology of physical space, how personality is expressed in everyday contexts, and on new methods for collecting data in the behavioral sciences. His approach is ecological, emphasizing the importance of studying individuals in their natural habitats. His current work aims to use psychology to inform architectural practice. His book “Snoop: What your stuff says about you” is based on the idea that we deliberately and inadvertently express our personalities in the environments in which we live and work. Clarivate have identified him as one of the most highly cited scientists in the world.  

Navigating the complexities of groundbreaking treatments can create headwinds. With innovations like Pulsed Field Ablation (PFA) at the forefront, challenges such as financial uncertainties, regulatory shifts, and global adoption become paramount. Join us for an insightful discussion on how global partners address these challenges, focusing on safety & efficacy, financial impacts, and clinical differentiation in areas where baseline data is scarce. Background on PFA: Pulsed Field Ablation (PFA) is a groundbreaking nonthermal energy source that is rapidly transforming atrial fibrillation (AF) treatment, affecting up to 38 million people worldwide. Unlike traditional heat or cold methods, PFA uses high-voltage electrical fields in microseconds for precise cell necrosis, marking a significant advancement in cardiology. Guests: - Juliane Ray, Global Head of Medtech Strategy, Clarivate (Moderator) - Annette Boyle, Editor, BioWorld MedTech - Dee Chaudhary, Principal Commercial Strategy Consulting, Clarivate - Pankhil Ghandhi, Senior Team Lead, Medtech Insights, Clarivate - David Begley, MD, Clinical Director in Cardiology, Royal Papworth HospitalSend us a message! Follow Medical Alley on social media on LinkedIn, Facebook, Twitter and Instagram.

In this concluding episode of Season 3 of "Ideas to Innovation," we reflect on our journey through the episodes published in 2024 that highlight the conversations we've enjoyed with some of the brightest minds in education, healthcare and intellectual property law.     In episode 6 in February, we explored America's literacy challenge with documentary filmmaker Jenny Mackenzie. Jenny shared her personal connection to literacy and discussed the innovative strategies being used to promote reading rights across the United States. Her insights into reading proficiency and educational reform were both eye-opening and inspiring.     March brought us a conversation with Renée Aguiar-Lucander, CEO of Calliditas Therapeutics, in episode 7, who detailed the groundbreaking journey of Tarpeyo, a drug that promises to revolutionize the treatment of kidney disease. Renée explained the innovative path to FDA approval, setting new benchmarks in the pharmaceutical industry.     We delved into the impact of artificial intelligence on intellectual property law in episode 8 in April, with Jay Myers from Seyfarth Shaw and Arun Hill from Clarivate. They provided valuable insights into how AI is transforming trademark searches, infringement monitoring and strategic brand decisions while addressing the ethical challenges that come with these advancements.     As we wrap up Season 3, we hope the episodes have informed, inspired, and entertained you. You can also listen to the Season 3 episodes from 2023 – our end-of-year episode summarizes the five stories we shared between September and December.      "Ideas to Innovation" will return later this year with more stories that showcase the power of human intellect and innovation.     Stay curious, and thank you for listening.  

Audio from Day One, Part Three of the 2023 Charleston In Between Today we're featuring Audio from Day One, Part Three of the 2023 Charleston In Between.  In this session, we'll discuss defining integrity standards in publishing. This session is presented by Nadita Quaderi, Clarivate, and was organized and moderated by Sven Fund, Managing Director, Reviewer Credits, and Leah Hinds, Executive Director, Charleston Hub. Video of the presentation available at:  https://youtu.be/2dpB3WERvcY?si=RXlb_GlUIGOYo9WQ Social Media: https://www.linkedin.com/in/nanditaquaderi/ https://www.linkedin.com/in/svenfund/ https://www.linkedin.com/in/leah-hinds-297b31144/ Twitter: Keywords: #Research, #ResearchIntegrity, #ResearchSharing, #PublishingIntegrity, #PeerReview, #AcademicWriting, #ScholarlyWriting, #ScholarlyResource, #AcademicJournal,  #scholcomm, #collaboration,  #engagement, #problemsolvers, #academics, #publishing, #ScholarlyPublishing, #publishingnews, #informationaccess, #AcademicPublishing, #libraries, #librarians, #information, #2023ChsConf,  #LibrariesAndVendors, #libraryvendors, #LibrariesAndPublishers, #libraryissues, #libraryneeds,#librarylove, #librarychallenges, #libraryconference #podcast  

Audio from Day One of the 2023 Charleston In Between Today we're featuring Audio from Day One of the 2023 Charleston In Between.  In this session, we'll discuss why integrity in research and publishing matters, and Institutions, libraries and their roles in research integrity. Also, how to define integrity standards in publishing with integrity. This session is presented by Mohammed Hosseini,  Northwestern University, Curtis Brundy of Iowa State University, and Nadita Quaderi, Clarivate. The session is organized and moderated by Sven Fund, Managing Director, Reviewer Credits, and Leah Hinds, Executive Director for the Charleston Hub. Video of the presentation available at:  https://www.youtube.com/watch?v=3DSmTRjDkIE&t=38s Social Media: https://www.linkedin.com/in/hosseinimohammad/ https://www.linkedin.com/in/curtisbrundy/ https://www.linkedin.com/in/nanditaquaderi/ https://www.linkedin.com/in/svenfund/ https://www.linkedin.com/in/leah-hinds-297b31144/ Twitter: Keywords: #Research, #ResearchIntegrity, #ResearchSharing, #PublishingIntegrity, #PeerReview, #AcademicWriting, #ScholarlyWriting, #ScholarlyResource, #AcademicJournal,  #scholcomm, #collaboration,  #engagement, #problemsolvers, #academics, #publishing, #ScholarlyPublishing, #publishingnews, #informationaccess, #AcademicPublishing, #libraries, #librarians, #information, #2023ChsConf,  #LibrariesAndVendors, #libraryvendors, #LibrariesAndPublishers, #libraryissues, #libraryneeds,#librarylove, #librarychallenges, #libraryconference #podcast  

The BRAND NEW 2nd Generation Tone Devices are NOW SHIPPING!! Order HERE Hi friends! This episode is featuring Dr. Stuart Phillips! See full bio below. WIN $800 in Energybits and a Tone LUX Diamond red light therapy panel! Contest details HERE Get 20% OFF Energybits Spirulina and Chlorella with the code KETOGIRL Energybits.com Get $50 OFF The Tone LUX Red Light Therapy Panels when combined with a pre-order for the new Tone LUX Crystal Mask - use the code TONELUXSAVE50 - Click HERE To Shop! Now available! Tone Protein- Click Here to Check it out! - Follow @optimalproteinpodcast on Instagram to see visuals and posts mentioned on this podcast. Follow Vanessa on instagram to see her meals, recipes, informative posts and much more! Click here @ketogenicgirl Link to join the facebook group for the podcast: https://www.facebook.com/groups/2017506024952802/   Stuart Phillips obtained a Ph.D. from the University of Waterloo in Human Physiology in 1995. He joined McMaster University in 1999 and is currently a full Professor in the Department of Kinesiology and School of Medicine at McMaster University. He is Tier 1 Canada Research Chair in Skeletal Muscle Health. He is also the Director of the McMaster Centre for Nutrition, Exercise, and Health Research and the Physical Activity Centre of Excellence. Dr. Phillips has authored more than 200 original research papers and 75 reviews. In 2018 and 2019, he was named to Clarivate's Highly Cited Researchers he list as a being in the top 1% of all cited researchers in nutrition and exercise research. Dr. Phillips is a fellow of the American College of Sports Medicine and the Canadian Academy of Health Sciences. - This podcast content does not constitute an attempt to practice medicine and does not establish a doctor-patient relationship. Please consult a qualified healthcare provider for medical advice and personal health questions. Prior to beginning a new diet you should undergo a health screening with your physician to confirm that a new diet is suitable for you and to out any conditions and contraindications that may pose risks or are incompatible with a new diet, including by way of example: conditions affecting the kidneys, liver or pancreas; muscular dystrophy; pregnancy; breast-feeding; being underweight; eating disorders; any health condition that requires a special diet [other conditions or contraindications]; hypoglycemia; or type 1 diabetes. A new diet may or may not be appropriate if you have type 2 diabetes, so you must consult with your physician if you have this condition. Anyone under the age of 18 should consult with their physician and their parents or legal guardian before beginning such a diet. Use of Ketogenic Girl videos are subject to the Ketogenicgirl.com Terms of Use and Medical Disclaimer. All rights reserved. If you do not agree with these terms, do not listen to, or view any Ketogenic Girl podcasts or videos.

Today we continue our discussion in part two about the relationship between our stuff and our personal identities with Dr. Sam Gosling. Sam Gosling is a Professor of Psychology at the University of Texas, Austin. He did his doctoral work at the University of California at Berkeley, where his dissertation focused on personality in spotted hyenas. His current research focuses on the psychology of physical space, how personality is expressed in everyday contexts in daily life, and in new methods for collecting data in the behavioral sciences. His approach is ecological, emphasizing the importance of studying individuals in the contexts of their natural habitats. He is an elected fellow of the Association for Psychological Science and Society for Personality and Social Psychology (or SPSP for short). Dr. Gosling is the recipient of the American Psychological Association's Distinguished Scientific Award for Early Career Contribution, the Carol and Ed Diener Award in Personality Psychology, and SPSP's award for methodological innovation. His book, “Snoop: What your stuff says about you” which we'll also discuss, is based on the idea that we deliberately and inadvertently express our personalities in the environments in which we live and work. Clarivate, which is global leader in providing trusted insights and analytics, have identified him as one of the most highly cited scientists in the world. SOURCES: https://docs.google.com/document/d/1VbPjsPW26ZUte4wkH9h3s2TmcBHPOp_yTBgVq3C2AHk/edit?usp=sharing MUSIC: "Sun Shines Through the Leaves" --- ©2022, ©2024 The Furious Curious

The remarkable journey of Calliditas Therapeutics and its groundbreaking drug, Tarpeyo, sheds light on the company's innovative strategies and relentless pursuit of excellence that led to the successful approval of Tarpeyo by the U.S. Food and Drug Administration (FDA) for the treatment of a specific kidney disease. Our guest in this episode, Renée Aguiar-Lucander, CEO of Calliditas Therapeutics, reveals how their pioneering approach to drug development has set a new benchmark in the pharmaceutical industry.  We explore how Calliditas Therapeutics' groundbreaking work in securing FDA approval not only marks a significant milestone for the company but also inspires a new wave of innovation in the treatment of kidney diseases. Discover the power of pioneering drug development and the bright future it heralds for patients worldwide.  This episode also features insights from Mike Ward, Global Head of Life Sciences and Healthcare Thought Leadership at Clarivate, highlighting the importance of the Drugs to Watch 2024 report and the potential of Tarpeyo – one of 13 drugs to watch included in the report – to significantly improve patient outcomes.  Discover a story of resilience, innovation, and success behind Tarpeyo's journey to the American market, and the broader implications for the pharmaceutical industry's approach to drug development and regulatory approval. 

Success lies in adapting products based on real-world feedback, ensuring your business aligns with your customers' genuine desires. This is exactly what Chris Takcas, Sales Manager at Clarivate and host Marc Gonyea sit down to discuss in the latest episode of Tech Sales is for Hustlers, outlining the need for products and businesses to be user-centric, rather than just technically sound.  Chris talks about how he goes about adapting products based on feedback, highlighting the importance of user-friendly interfaces. Not only that, but he shares his evolution from transactional to solution-based sales, emphasizing the value of diagnosing customer problems holistically. Chris also underscores the role of coaching in sales growth, drawing parallels between managing a gym and nurturing sales talent.

For nearly half a century, the Journal Citation Reports, or JCR, have been “must reading” in universities around the world. Dr. Nandita Quaderi, a senior vice president and the editor in chief for Web of Science at Clarivate, shares the latest developments in the JCR's ongoing evolution.

Audio from the 2023 Charleston Conference Leadership Interview Series. Heather Staines, Senior Strategy Consultant, Delta Think and a Director for the Charleston Conference interviews Bar Veinstein, President, Academia & Government, Clarivate. Heather and Bar talk about his background and how he came to join Clarivate in a newly created position last year, how technology in libraries has changed and how libraries have been change agents as early adopters of technology ahead of other industries, not just in the libraries but beyond campus. He says Clarivate's mission is to offer services to help libraries expand beyond the core for libraries to be successful. Bar says Clarivate is constantly searching for ways to help the library engage and interact with other stakeholders on campus to show and extend the value of the libraries to help everyone be successful. Bar also talks about his experiences with the Charleston Conference and the keynote panel presentation on the need for scholarly publishing and the impact of open research. Video of the Interview is available at: https://www.youtube.com/watch?v=6_ZEzByVSiI  Social Media: LinkedIn: https://www.linkedin.com/in/heatherstaines/ https://www.linkedin.com/in/barveinstein/ Keywords:   #Clarivate, #technology, #innovation, #AI, #GenAI, #thinkforward, #LeadershipDevelopment, #entrepreneurship, #leaders, #leadership, #2023ChsConf, #libraries, #librarianship, #LibraryNeeds, #LibraryLove, #ScholarlyPublishing, #AcademicPublishing, #publishing, #LibrariesAndPublishers, #podcasts

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. Today, we have a jam-packed episode with the latest news and trends in the industry. Let's dive in!In the pharmaceutical industry, drugmakers are facing five important questions in 2024. These include competition in obesity, the next era of oncology, and the impact of a contentious drug pricing law. Pfizer had a difficult year in 2023, but we had the opportunity to hear from Albert Bourla, the company's CEO, about their plans for the future. PureTech's Daphne Zohar is also making waves with her neuroscience startups. Despite layoffs in the biotech industry, recent deal-making and stock market momentum have brought some optimism. Biotech mergers and acquisitions are picking back up, with $45 billion worth of deals announced in the past six weeks. We also have sponsored content about leveraging artificial intelligence in patient support and real-world data in clinical trials.Switching gears to healthcare, hospitals are facing slim operating margins and experts predict they will focus on trimming unnecessary expenses and investing strategically in labor. The Department of Health and Human Services has published an updated provider conscience rule, balancing religious freedom rights with patients' access to care. The Federal Trade Commission has reached a settlement with a data broker to protect patients' privacy. Sutter Health has appointed a new CFO, Raju Iyer, who will be responsible for financial planning. And don't forget about FedEx Office's sponsored content on how high-quality printed materials can boost patient relationships.In biotech news, Myrobalan has raised $24 million to advance its neurorestorative drugs for neurological disorders. Alcon has reported promising data from a Phase III trial for its drops to treat dry eye disease. Taco Bell is hosting a Las Vegas fan experience ahead of Super Bowl LVIII, showcasing new products and partnerships. Walmart+ has enlisted TV personality Andy Cohen for its "Quitter's Day" campaign. Honda has launched its "Chasing Greatness" campaign featuring indie artist Bishop Briggs. And we have the top 50 content marketing brands and eight predictions for 2024 in the marketing industry.Two biotech companies, 4D Molecular Therapeutics and Arbor Biotechnologies, have announced a collaboration to develop treatments for central nervous system diseases. We also discuss the potential of artificial intelligence in drug discovery and development. And we wrap up with news on pharmaceutical companies using tactics to maintain high drug prices, Clarivate's "drugs to watch" list for 2024, and various acquisitions and layoffs in the biopharma industry.Abzena is offering a new application note for its Thiobridge™ technology in ADC development, highlighting improved stability and efficacy. Medtronic is focused on delivering durable revenue and profit growth, while Dexcom plans to launch a new CGM device. Amazon has launched a chronic condition management portal, and Walgreens has settled a drug pricing dispute with Humana. Nonprofit hospitals and health systems are financially stable despite declining operating margins. And digital health funding reached its lowest level since 2019.That's all for today's episode of Pharma and Biotech Daily. Stay tuned for more news and updates in the industry. Remember, we give you only what's important to hear!

Over the past year, the Ideas to Innovation podcast from Clarivate took listeners on a special journey through a world where curiosity meets ingenuity. In each of 15 episodes published in 2023, we told stories of people thinking forward in the real world, highlighting those who not only dared to dream but also transformed their dreams into reality. Our conversations with experts weren't just talks; they were narratives of change, powerful examples of how fresh insights are solving some of the world's most complex challenges.   For this “Best of 2023” episode, we showcase three compelling stories, each of which serves a testament to the spirit of innovation. You'll first hear from an associate professor who is known as a ‘scientific sleuth' for his uncanny ability to identify falsified data in published academic research. Next, two guests share their stories about a rare hereditary disease, its devastating impacts and the role and work of scientific research in finding answers. In our final segment, an accomplished scientist, engineer, and innovator with 77 patents to her name talks about her work in breaking down complex problems, her most surprising discovery, and finding solutions that stick. We hope you enjoy this recap and continue joining us as we traverse a landscape rich in creativity and innovation, meeting extraordinary minds and witnessing their groundbreaking work in real time. 

Rapid advancements in technology and science are shaping a new era, with artificial intelligence and synthetic biology, or “syn-bio,” at the forefront. Heralded as the next big leap in science, syn-bio involves redesigning organisms for useful purposes by engineering them to have new abilities. The importance of syn-bio for people and our planet cannot be overstated. It offers novel ways of producing almost anything that human beings consume, from flavors and fabrics to foods and fuels. Today, the combination of syn-bio and AI – two of the most potent realms of science and technology – promises to unravel solutions to our most pressing challenges, including Earth's food and water, the environment and sustainability, bioenergy, and human health care.  One widely recognized trailblazer in syn-bio is Jim Collins, professor of medical engineering and science and professor of biological engineering at MIT. He is also a core founding faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University. In the latest episode of the “Ideas to Innovation Season 3” podcast from Clarivate, Collins helps listeners navigate through the exciting but complex landscape of syn-bio. He also discusses what it was like to be named a Citation Laureate 2023 for his pioneering work in synthetic gene circuits, which launched the field of syn-bio. Each year since 2002, the Citation Laureates program from Clarivate recognizes a small group of highly cited scientists and economists whose influence is comparable to that of past and future Nobel Prize winners. 

Mark Garlinghouse Director, Business Development @The Lens Mark Garlinghouse is responsible for business development at The Lens. He joined The Lens in 2019 to support its transition to financial sustainability. Mark has over 25 years of experience in the information industry, working with Information Handling Services (now S&P Global Engineering Solution) and the Institute for Scientific Information/Thomson Reuters (now Clarivate) in various business development and leadership roles. Aaron Ballagh Manager, Scholarly Content @The Lens Aaron is the Scholarly Content Manager for The Lens. Starting his career in fisheries research, Aaron moved into research information management when he joined the Research Services team at James Cook University as a research data and systems analyst. He then joined the Research Services Division at The Australian National University working on the university's research information systems to analyze and model research performance. As research data manager, Aaron submitted the Excellence in Research for Australia submission for ANU before joining Springer Nature as data product manager for the Nature Index. About the webinar series This webinar series is co-organised by: UbuntuNet Alliance: https://ubuntunet.net/ and Access 2 Perspectives: https://access2perspectives.org/ as part of the ORCID Global Participation Program: https://info.orcid.org/global-participation-program/ The Global Participation Fund: https://info.orcid.org/global-participation-program/global-participation-fund/ Learn more about ORCID: https://orcid.org/ Link to the webinar series: https://africarxiv.pubpub.org/webinars AfricArXiv website: africarxiv.org ⁠ORCID⁠ is the persistent identifier for researchers to share their accomplishments (research articles, data, etc with funding agencies, publishers, data repositories, and other research workflows. ⁠AfricArXiv⁠ is a community-led digital archive for African research communication. By enhancing the visibility of African research, we enable discoverability and collaboration opportunities for African scientists on the continent as well as globally. Find more podcast episodes here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://access2perspectives.pubpub.org/podcast⁠⁠⁠⁠⁠⁠⁠ Host:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Dr Jo Havemann⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ORCID iD ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠0000-0002-6157-1494 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Editing: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Ebuka Ezeike⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Music:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Alex Lustig⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, produced by⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Kitty Kat ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ License:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Attribution 4.0 International (CC BY 4.0)   ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ At Access 2 Perspectives, we guide you in your complete research workflow toward state-of-the-art research practices and in full compliance with funding and publishing requirements. Leverage your research projects to higher efficiency and increased collaboration opportunities while fostering your explorative spirit and joy. Website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://access2perspectives.pubpub.org⁠⁠⁠⁠⁠⁠⁠ --- Send in a voice message: https://podcasters.spotify.com/pod/show/access2perspectives/message

Alle Infos zu ausgewählten Werbepartnern findest du hier.  Das Buch zum Podcast? JETZT BESTELLEN.  Lieber als Newsletter? Geht auch.  Pinduoduo macht Konkurrenten arm und den Gründer reich. RWE macht seine Aktionäre reich, und das am besten mit grüner Energie. Shein will sich Reichtum an der Börse holen. Clarivate (WKN: A2PLSH) hat enorm viele Forschungsdaten und seit neuestem das Orakel von Boston an Bord. Kommt jetzt der Turnaround? Airbnb (WKN: A2QG35) ist eigentlich eine Bank. Diesen Podcast vom 29.11.2023, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Over the past half century, the semiconductor technology landscape has been evolving rapidly, underpinning the digital transformations we witness across the various spheres of life today. Sometimes referred to as integrated circuits or microchips, semiconductors are the backbone of modern electronics. In devices of every type, from simple gadgets to complex systems like computers, cars and household appliances, semiconductors have led to them being smaller or faster or more reliable. More inconspicuously, semiconductors are now enabling innovations in healthcare to flourish.    One company, imec, stands as a vanguard in this area. Their work promises to enable smart health concepts such as precision medicine and genomics to be brought within everyone's reach, resulting in personalized treatments with better outcomes and lower costs. Joining the latest episode of the “Ideas to Innovation Season 3” podcast from Clarivate is Peter Peumans, Chief Technology Officer - Healthcare Technologies and Senior Fellow at Belgium-based imec.  He and Ed White of Clarivate discuss how innovations in semiconductors led imec to be named one of 36 companies in this year's Innovators to Watch report from Clarivate. The report – guided by Ed in his role as vice president and principal analyst for IP and Innovation Research at Clarivate –identifies organizations that demonstrate both exceptional potential and above-the-bar innovation excellence. 

The concept of academic libraries has evolved from humble beginnings five thousand years ago to the expansive network that exists today in public schools, colleges, and universities across the United States. It's easy to see why libraries are worth supporting. They continue to facilitate academic excellence, embrace advancements in technology and foster community and collaboration. Still, looking ahead, academic libraries face several significant challenges, including – perhaps most importantly – the significant cost for their support.     Championing the cause of libraries is the mission of our latest guest on the “Ideas to Innovation Season 3” podcast from Clarivate. John Chrastka serves as executive director of EveryLibrary, a non-profit group that builds voter support for academic libraries and helps them secure funding as well. To advance this mission, Clarivate recently announced a partnership with EveryLibrary that leverages the strengths of the two organizations through dedicated resources and advocacy. John is long-time library trustee, supporter and advocate for academic libraries. Prior to his current role, he served as former partner in AssociaDirect, a Chicago, Illinois-based consultancy focused on support associations in membership recruitment, conference, and governance activities. 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.In our first news, we have a summary of an on-demand webinar that discusses how real-world data (RWD) can be leveraged in rare disease research. The use of RWD in clinical trials and drug development for rare diseases is explored by experts from Pfizer and Clarivate. They highlight the importance of RWD in narrowing the gap of knowledge surrounding rare diseases and how it can enhance clinical trials and improve drug development processes. Challenges associated with harnessing RWD effectively are also addressed, along with best practices for overcoming these obstacles. The goal is to optimize rare disease research by leveraging RWD and improving drug development efficiency.Moving on to our next news, we have a promotion for an on-demand webinar titled "High-Throughput Process & Analytical Platforms to Accelerate Gene Therapy Scale-Up." This webinar discusses various topics related to gene therapy scale-up and how innovative platforms can revolutionize the process. Some key points covered include serotype agnostic analytics for AAV manufacturing, challenges in scaling up to larger bioreactors, using an advanced platform with a reduced number of plasmids, and Resilience and Lacerta's innovations. Experts in the field share their insights, and interested individuals can connect with the Resilience team for support in gene therapy process and analytical development work.In regulatory news, the FDA has placed a partial clinical hold on two studies of Innate Pharma's investigational therapy lacutamab following a patient death from the rare blood disease hemophagocytic lymphohistiocytosis. Innate Pharma is working closely with the FDA to address the agency's concerns and provide the necessary data. In other news, an FDA advisory committee has backed the use of US WorldMeds' investigational drug for high-risk neuroblastoma, despite the lack of a randomized controlled trial. This decision could set a precedent for future drug approvals without randomized controlled trial data. Japan-based pharma company Kyowa Kirin is also acquiring Orchard Therapeutics pending regulatory approvals, and Johnson & Johnson's spravato has shown promising results in a phase III head-to-head study.Shifting gears to marketing and advertising, we discuss the importance of connected TV for marketers and how the Hollywood shutdown could disrupt the ad market. Disney's innovative holiday marketing strategies are highlighted, along with Olaplex's unique approach to addressing dupe culture on TikTok. Three Olives Vodka is mentioned for using AI to plan the perfect party, and Meta (formerly known as Facebook) is expanding access to its generative AI tools. Target has launched an immersive toy experience for online shoppers, allowing them to explore a virtual room of products.In the rare disease space, we delve into regulatory challenges related to the use of biomarkers to measure efficacy. The FDA recently approved Novo Nordisk's drug rivfloza for patients with primary hyperoxaluria, but there are concerns about shortcomings in regulatory policies when it comes to biomarkers for rare diseases. Leaders in the pharmaceutical industry who are skilled at translating scientific research into products that regulators see value in are recognized on this year's Pharmavoice 100 list.Lastly, we address the challenges faced by health systems in their workforce due to a volatile economy. Burnout and high turnover rates persist despite efforts to raise wages and strengthen hiring. The nursing shortage is a major issue, and efforts are being made to address the gender pay gap among physicians. On a positive note, there has been a record number of residency matches for 2023, providing insights into current labor trends in healthcare.That wraps up today's episode of Pharma and Biotech daily. Stay tuned for more important news and updates in

Artificial intelligence is all around us and it's revolutionizing our world in many ways. In life sciences and healthcare, AI-powered technologies are instrumental in tasks such as diagnostics, precision medicine and even robotic surgery. And the transformative aspect of generative AI is already being felt in areas such as pharmaceutical research, epidemiology and telemedicine. There are projections that the global market for AI in life sciences and healthcare will be $6.7 billion USD by 2030. What is driving such remarkable growth and how rosy is this picture?     Joining us at the start of a new season three of the “Ideas to Innovation” podcast from Clarivate is Henry Levy, who has plenty to say about AI and what it will and won't enable us to achieve. Henry joined Clarivate earlier this year as President, Life Sciences and Healthcare (LS&H). He leads the teams focused on developing solutions that enable life sciences and healthcare companies and providers to create a healthier tomorrow by connecting them to transformative intelligence and data technology to improve patient lives. With more than 25 years of experience, Henry is the author of multiple articles on drug development and tech trends and a frequent speaker at industry forums. He holds a bachelor's degree in bioengineering from the University of Pennsylvania.

Today, innovation is key to driving business growth and competitive advantage, with intellectual property or IP sitting at the very heart of this strategy. In recent years we've witnessed some remarkable strides across the globe in bridging the gender gap in the IP sector. Yet, according to the World Intellectual Property Organization, only 16 percent of international patent applications are filed by women inventors. At this rate, the WIPO doesn't expect to achieve gender parity before 2064. That's almost 40 years into the future. So, while progress is being made, clearly much more must be done to quickly close this gap as well as a similar gap in career opportunities for minorities.    Tarianna Stewart – our featured guest in the latest episode of the Ideas to Innovation Season 2 podcast from Clarivate – ventured into her IP career by accident. “I happened to learn about IP during my Ph.D. program and thought, ‘this seems interesting… maybe a little bit better than working in the lab.'” Now an experienced biomedical scientist and accomplished IP professional at the technology unit of New York University in New York City, Tarianna has smart advice for women and people of color who seek to follow in her footsteps and pursue careers in IP and innovation. In our podcast discussion, she recalls how she “fell in love with the tech transfer space,” and offers a ‘been-there-done-that' perspective on what she believes it will take to foster a more inclusive IP and innovation landscape for the benefit of all involved. 

In today's episode, we're talking with Jonathan Adams, Chief Scientist, Institute of Scientific Information, a part of Clarivate.  Jonathan is interviewed by Matthew Ismail, a Conference Director and Editor in Chief of the Charleston Briefings. Jonathan Adams is a jack of all trades in the scholarly communication field. He is a scientist who taught in higher education and published a successful book in the field of biology. He has been an Assistant Secretary and Science Policy Advisor to the UK government. He has founded a startup related to his research and teaching. He has been in charge of research evaluation at Digital Science and Thomson Reuters. And now he is Chief Scientist at ISI with Clarivate Analytics. He is very well qualified to discuss the research landscape! In this podcast, Jonathan and Matthew discuss the recent report published by ISI, U.S. Research Trends:  The Impact Of Globalization and Collaboration. This report discusses many interesting topics, but perhaps the most relevant finding is that US STEM research, while still strong, is no longer dominant in the world. Jonathan and Matthew discuss the factors that have made the US less competitive in STEM research. Social Media: LinkedIn: https://www.linkedin.com/in/matthew-ismail-1a6282a/ https://www.linkedin.com/in/jonathan-adams-5a02188b/ Keywords: #Clarivate, #WebofScience, #data, #DataScientists, #Innovation, #technology, #learning, #education, #knowledge #research, #collaboration, #libraries, #librarianship, #LibraryNeeds, #LibraryLove, #AcademicPublishing, #ScholarlyPublishing, #publishing, #podcasts

In der heutigen XXL-Folge „Alles auf Aktien“ sprechen der Tech-Investor Pip Klöckner und Finanzjournalist Holger Zschäpitz über reiche Norweger dank Aktien, Zinsangst an den Märkten, den weltweit etwas abebbenden Tourismusboom und Wachstumssorgen beim angesagten Sneaker-Haus On Holding. Außerdem geht es um JPM Chase, Bank of America, Norwegischer Staatsfonds, Encavis, SMA Solar, HomeToGo, Sea Ltd, Jumia, PayPal, Clarivate, Seadrill, Constellation Brands, NuStar Energy, Phillips 66, Position Pinterest, On Holding, Nvidia, Marvell, Super Micro Computer, Google, Meta, Adobe, Microsoft, Palantir, C3.AI, IBM, Xtrackers Artificial Intelligence (WKN: A2JAV15). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Guests Karen Carey, BioWorld's managing editor, and Mike Ward, Clarivate's global head of Life Sciences and Healthcare Thought Leadership, discuss the deals, financing and M&A landscape for the first half of 2023 and how U.K. biopharmas are faring post Brexit.

Recorded on 07/26/23 Over the last decade, data and analytics have become increasingly engrained in the healthcare system. Given the evolving landscape, we wanted to provide a deeper look into the different types of healthcare data currently available, as well as the users and use cases. This podcast is intended to be the first in a series on healthcare data, and in this episode we provide a general overview of how healthcare data is currently being used, with subsequent podcasts exploring subsets of healthcare data in more depth. To discuss this topic, we are joined by Paul Reuscher. After spending the early part of his career in academia researching health economic outcomes, Mr. Reuscher eventually joined IMS Health, now a part of IQVIA, first as a product manager then eventually helping develop what is now IQVIA's anonymized patient data solution. He subsequently led a similar development program for DRG, which is now a part of Clarivate. Paul currently is Vice President of Clinical Data Products at Forian, a healthcare data intelligence company. For Disclosures, click here bit.ly/3cPHkNW

Growth: it's a mindset.In this episode of the Sales Code Leadership Podcast, Kevin chats with the delightful Leigh Ashton, founder and CEO of Sales Consultancy, about exploring the power of growth mindsets and their profound impact on revolutionizing your sales approach.Leigh shares with Kevin that although high-performing A-players are undoubtedly valuable, fostering a growth culture and uplifting the non-A players within your team can remarkably benefit your organization.Prepare to be inspired as the link between mindset and behavior is unveiled, demonstrating how adopting the right mentality can drive exceptional results. Drawing on her extensive expertise, Leigh also offers invaluable advice for leaders, empowering them to foster progress and development within their teams. Leigh Ashton is the author of two books, a speaker, trainer and coach...and the founder of The Sales Consultancy.She works with Sales Leaders and teams to develop Sales Growth Mindset and healthy sales growth cultures that support personal development, mental well-being and sales success.Her programmes develop Sales Leaders teams to think and perform at a higher level and her clients include NatWest, Wright Medical, AVEVA, Motorpoint, British Airways, Stryker, Headspace, Siemens, Clarivate, Oracle…and more.She's known for increasing sales...and leaving people feeling confident, motivated and inspired to go beyond their comfort zone to achieve greater sales and leadership success!Connect with Leigh: https://www.linkedin.com/in/leighashton1/The podcast is brought to you by Sales Code, helping revenue leaders unlock added value in B2B SaaS sales teams. Your views on our podcast are always welcome, as well as any questions you might have for our podcast guests.Connect with host Kevin Thiele here.

A person born this year is expected to live about 73 years, according to the World Health Organization. But 73 doesn't reveal the full picture. According to a WHO report published in May, advances in science, related technologies and other factors have helped increase life expectancy worldwide by six years between 2000 and 2019.  Good news, right? However, it's also true that 80 percent of premature deaths could be avoided if patients and healthcare professionals had the right information at the right time to make better decisions. That's where artificial intelligence comes in. Today, Patient Connect, a biopharma intelligence company that's part of Clarivate, is integrating AI into clinical software at point of care for patients around the world, such as, for example, the two million people in the U.S. who suffer from heart failure. These new AI tools are enabling more than a million physicians to provide better care for those suffering from a wide variety of diseases by identifying the most at-risk patients or the patients with the most unmet needs.     To explain how such sophisticated solutions provide better and best care for patients, we welcome back Dr. Grace Lomax to the “Ideas to Innovation Season 2” podcast from Clarivate. Grace founded Patient Connect with her sister, Zoe Barker, in 2008, and the company was acquired by Clarivate in 2021. Patient Connect engagement solutions improve patient outcomes by delivering clinical messaging to the workflows of physicians and pharmacists at the point of patient contact. This messaging helps guide patients to better understand their treatment and disease and empower them to make informed healthcare decisions.     For more information on the many ways Clarivate is using AI to deliver the highest quality content and insights to customers, go to www.clarivate/ai 

Among the consequences of COVID-19 is its adverse impact on the mental health and wellbeing among university students in the United States.  Today's students deal with many challenges from coursework, relationships and adjustments to campus life, to economic strain, social injustice, mass violence and various forms of loss related to the pandemic. In a 2021 survey, nearly 75 percent of college presidents listed students' mental health as their most pressing issue. And key findings from a report released this year by non-profit Mental Health America shows more than 10 percent of young people are experiencing depression that severely impairs their ability to function at school or work, at home, with family or in their social life.  Many school leaders have started to think outside the box about how to help. They're finding ways to incorporate a broader culture of wellness into their policies, systems and day-to-day campus life. In this episode of “Ideas to Innovation Season 2” from Clarivate, we speak with Lisa O'Donnell, assistant professor for the department of social work at Wayne State University in Detroit, Michigan. An expert in bipolar disorder and severe mental illness, she brings a compelling perspective to the topic of university students and mental health. Lisa has served as a clinician for the state of Michigan for more than 18 years, primarily working with adults who have severe mental illness as well as anxiety disorders and OCD-related disorders.   For information on subscriptions to mental health e-books from ProQuest, part of Clarivate, go to https://bit.ly/proquestmentalhealth 

Audio from the 2022 Charleston Conference from a Neopolitan Session titled “Whole EBook ILL Redux.” In this session, panelists discussed results and updates on ProQuest's, a part of Clarivate,  successful Whole Ebook ILL pilot. This session was presented by Allen Jones (the New School), Whitney Murphy (ProQuest), George Machovec (Colorado Alliance of Research Libraries) , Sylvia Bonadio (Brill), and Lisa Nachtigall (Oxford University Press).  Video of the presentation available at: https://youtu.be/5-XQUXZGia4 Social Media: https://www.linkedin.com/in/ajones3066/ https://www.linkedin.com/in/wkmurphy/ https://www.linkedin.com/in/george-machovec-3a649a4/ https://www.linkedin.com/in/sylviabonadio/ https://www.linkedin.com/in/lisanachtigall/  Keywords: #LibraryResources, #eresources, #ebooks, #ebookLending, #interlibrarylending, #ProQuest, #EbookCentral,  #pilotproject, #technology, #innovation, #collaboration,#engagement, #problemsolvers, #libraries, #librarians, #information, #ChsConf,  #LibrariesAndVendors, #LibrariesAndPublishers, #libraryissues, #libraryneeds,#librarylove, #librarychallenges, #libraryconference #podcast  

Every year, Clarivate publishes a list of the Top 100 Global Innovators, companies and organizations that sit at the very top of the global innovation ecosystem, with the most consistent over-the-bar performance in innovation. Since the list began in 2012, only 19 companies can claim the distinction of being recognized continuously, year after year. One such company is 3M – the iconic global manufacturer and distributor well known for its cutting-edge scientific research and invention of groundbreaking products such as Post-it ® Notes, Scotchgard ™ Fabric Protector, and Thinsulate™ Insulation. In our latest episode of Ideas to Innovation Season 2, we'll learn how 3M is constantly pushing the boundaries of what's possible with science and innovation, where the power of science and the spark of human ingenuity come together in perfect harmony.    Read more - https://clarivate.com/podcasts/ideas-to-innovation-season-two/  

In February 2023, we celebrated women in science around the world for their significant contributions to science, technology, engineering and mathematics, collectively known as STEM.   In this episode we discuss the achievements and challenges for women in science and for girls who are thinking about careers in STEM fields with Dr. Rachel Webster, Director, Healthcare Research and Data Analysis, Oncology and Biosimilars at Clarivate.  Read more - https://clarivate.com/podcasts/ideas-to-innovation-season-two/  

Through its Citation Laureates program, Clarivate recognises individuals whose research publications are highly cited and whose contributions to their fields have been extremely influential, even transformative. This year, we named twenty world-class researchers from four countries as Citation Laureates. These are researchers whose work is deemed to be ‘of Nobel class', as demonstrated by analysis carried out by the ISI, and who are in the running for future Nobel honours. In this episode, you'll hear from two of this year's Citation Laureates who share insights into their work, how they got started, tips for young researchers, and more - Mary-Claire King, Professor of Medicine and of Genome Sciences, School of Medicine, at the University of Washington in Seattle, in the United States, recognized for demonstrating inherited susceptibility for breast and ovarian cancer and discovering the role played by mutations of the BRCA1 gene and Zhenan Bao, the K.K. Lee Professor of Chemical Engineering, and Director, Stanford Wearable Electronics Initiative (eWEAR), at Stanford University, California, recognized for the development of novel biomimetic applications of organic and polymeric electronic materials, including flexible ‘electronic skin.' Hosted on Acast. See acast.com/privacy for more information.

Today, with so much information available online, verification of information – who created it and who shared it – has become part of standard operating procedures in many enterprises to create a climate of trust surrounding information that can be used and acted upon. Nowhere is this truer than in the field of scientific research and reporting. In this episode, Nandita Quaderi, editor-in-chief for the Web of Science™ at Clarivate, shares her views on the topic of research integrity. She describes the importance of conducting and presenting research in a way that allows others to have trust and confidence in the methods used. And she warns of the dangers that occur in instances when the scholarly record cannot be trusted. Hosted on Acast. See acast.com/privacy for more information.

The healthcare industry worldwide is changing. Hospitals and healthcare systems in many countries are struggling to control costs, increase revenues, train and retain skilled employees, and treat and care for patients. In the business of health care, new approaches and ideas are coming to the fore as part of this journey to transform healthcare and ultimately change patients' lives. In this episode, podcast host Neville Hobson joins guests Mike Ward, Global Head of Life Sciences and Healthcare Thought Leadership at Clarivate, and Jerry Harrison, Rock and Roll Hall of Fame inductee as a member of Talking Heads, and healthcare and life sciences business entrepreneur, to discuss new approaches to investment that connect financial and human capital to communities in the healthcare space that share knowledge, interest and passion for healthcare innovation. And we examine how innovation is bringing some startling ideas in healthcare to life. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.

Today we continue our discussion in part two about the relationship between our stuff and our personal identities with Dr. Sam Gosling. Sam Gosling is a Professor of Psychology at the University of Texas, Austin. He did his doctoral work at the University of California at Berkeley, where his dissertation focused on personality in spotted hyenas. His current research focuses on the psychology of physical space, how personality is expressed in everyday contexts in daily life, and in new methods for collecting data in the behavioral sciences. His approach is ecological, emphasizing the importance of studying individuals in the contexts of their natural habitats. He is an elected fellow of the Association for Psychological Science and Society for Personality and Social Psychology (or SPSP for short). Dr. Gosling is the recipient of the American Psychological Association's Distinguished Scientific Award for Early Career Contribution, the Carol and Ed Diener Award in Personality Psychology, and SPSP's award for methodological innovation. His book, “Snoop: What your stuff says about you” which we'll also discuss, is based on the idea that we deliberately and inadvertently express our personalities in the environments in which we live and work. Clarivate, which is global leader in providing trusted insights and analytics, have identified him as one of the most highly cited scientists in the world. SOURCES: https://docs.google.com/document/d/1VbPjsPW26ZUte4wkH9h3s2TmcBHPOp_yTBgVq3C2AHk/edit?usp=sharing MUSIC: "Sun Shines Through the Leaves" --- ©2022 Britton Rice, Ben Santoriello

Today we're talking about the relationship between our stuff and our personal identities with Dr. Sam Gosling. Sam Gosling is a Professor of Psychology at the University of Texas, Austin. He did his doctoral work at the University of California at Berkeley, where his dissertation focused on personality in spotted hyenas. His current research focuses on the psychology of physical space, how personality is expressed in everyday contexts in daily life, and in new methods for collecting data in the behavioral sciences. His approach is ecological, emphasizing the importance of studying individuals in the contexts of their natural habitats. He is an elected fellow of the Association for Psychological Science and Society for Personality and Social Psychology (or SPSP for short). Dr. Gosling is the recipient of the American Psychological Association's Distinguished Scientific Award for Early Career Contribution, the Carol and Ed Diener Award in Personality Psychology, and SPSP's award for methodological innovation. His book, “Snoop: What your stuff says about you” which we'll also discuss, is based on the idea that we deliberately and inadvertently express our personalities in the environments in which we live and work. Clarivate, which is global leader in providing trusted insights and analytics, have identified him as one of the most highly cited scientists in the world. SOURCES: https://docs.google.com/document/d/1VbPjsPW26ZUte4wkH9h3s2TmcBHPOp_yTBgVq3C2AHk/edit?usp=sharing MUSIC: "Sun Shines Through the Leaves" _____ ©2022 Britton Rice, Ben Santoriello

This week we're diving into the OCLC lawsuit against Clarivate for its MetaDoor product, the implications of Roe being overturned, and ALAmageddon.  Becky Yoose (@yo_bj) / Twitter  Managing Data for Patron Privacy: Comprehensive Strategies for Libraries | ALA Store  About Us - LDH Consulting Services    Media mentioned Privacy Guides  https://gavialib.com/2022/06/stoning-goliath/ Library Loon article.  Karen Coyle - https://kcoyle.blogspot.com/2022/06/the-oclc-v-clarivate-dilemma.html  OCLC's non-profit status « The Thingology Blog Outsourcing the catalog department: A meditation inspired by the business and library literature - ScienceDirect SkyRiver vs. OCLC antitrust lawsuit – librarian.net

Every year, nearly 41 million people worldwide die prematurely from non-communicable diseases. Yet 80% of premature deaths could be avoided if patients and healthcare professionals alike had the right information at the right time to make better decisions.In this podcast Dr. Grace Lomax, the Clinical Director at Patient Connect, a part of Clarivate, shares her experience as a physician highlighting numerous unmet needs beyond just clinical issues – especially around healthcare literacy and education at the point of care. See acast.com/privacy for privacy and opt-out information.

For more than a decade, Ukraine has been a valuable part of scientific research with over 52,000 papers, many highly cited, written by Ukrainian researchers. This essential work came to a halt when Russia invaded Ukraine in February 2022. In this podcast Gali Halevi, Director at the Institute for Scientific Information at Clarivate, shares her perspectives on the impact on scientific research and discovery and how Clarivate is supporting displaced researchers in Ukraine. See acast.com/privacy for privacy and opt-out information.

In today's episode, we look at the state of the global innovation landscape and the direction of ideas still to come, as revealed by Top 100 Global Innovators 2022 from Clarivate – an annual list that recognizes the organizations that demonstrate consistent, above-the-bar innovation excellence and which sit at the very top of the global innovation ecosystem. Joining us are Davy Brown, Vice President and Chief Technology Officer of Industrial Solutions for TE Connectivity and Ed White, Chief Analyst and Vice President of IP and Innovation Research, at Clarivate. See acast.com/privacy for privacy and opt-out information.

Clarivate recently unveiled its annual list of Highly Cited Researchers, the “who's who” of the world's influential scientists and social scientists. The list from the Institute for Scientific Information recognizes some 6,600 researchers for demonstrating significant influence among their peers, as evidenced by the production of multiple highly cited papers that rank in the top 1% by citations for field and year, as indexed in the Web of Science over the last decade. Joining us today are David Pendlebury, Head of Research Analysis at the Institute for Scientific Information; Professor Liu Bin, Vice President of Research and Technology at the National University of Singapore; and Dr. Robin Drennan, Director of Research and Innovation at the University of the Witwatersrand, Johannesburg in South Africa. See acast.com/privacy for privacy and opt-out information.